Sonasoft and Diagnose Early Announce LOI for Health Data Partnership

Rhea-AI Summary

Sonasoft Corp. (OTCQB: SSFT) has entered a Letter of Intent (LOI) for a strategic partnership with Diagnose Early, aimed at enhancing patient outcomes through AI-driven early detection of diseases. The collaboration will utilize Sonasoft's AI platform, SAIBRE, to analyze extensive data from Diagnose Early labs. This partnership is backed by a Nobel Prize-winning team, including experts from Stanford and Harvard. The final terms of the agreement are expected to be completed by the end of May 2022.

Positive

• Strategic partnership with Diagnose Early enhances Sonasoft's market position.
• Collaboration utilizes advanced AI platform SAIBRE for data analysis.
• Partnership led by a Nobel Prize-winning team adds credibility.

Negative

• None.

SAN JOSE, CA, April 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sonasoft Corp. (OTCQB: SSFT) has executed an LOI for a pending strategic partnership with Diagnose Early. Sonasoft’s AI platform SAIBRE will be used to harness the massive amount of data that is captured through Diagnose Early labs. Diagnose Early is founded by a Nobel Prize-winning team including a Stanford M.D./Ph.D., a Nobel Laureate, and a Harvard Business School/UW Madison Engineer who came together through a shared vision of improving patient outcomes with innovative and early, non-invasive detection of biomarkers for cancer, neurological diseases, and infectious diseases.

We expect the terms of the deal to be finalized before the end of May 2022.

Notes

1. Sonasoft was founded in Silicon Valley in 2003. For more information about the company, please visit: https://www.sonasoft.com
2. Sonasoft SAIBRE is an end-to-end AI platform that can generate, monitor, and maintain AI models.
3. For investor-specific information, please visit: https://www.sonasoft.com/investors/

Investor Contact:
Josh Rose, Chief of Staff 
Sonasoft Corporation
Phone: (408) 708-4000

Forward-looking Statements

This release contains statements that constitute forward-looking statements. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

FAQ

What is the significance of Sonasoft's partnership with Diagnose Early?

The partnership aims to leverage Sonasoft's SAIBRE AI platform for early detection of diseases, enhancing patient outcomes.

When are the terms of the Sonasoft and Diagnose Early partnership expected to be finalized?

The terms are anticipated to be finalized by the end of May 2022.

Who are the key figures behind Diagnose Early?

Diagnose Early was founded by a Nobel Prize-winning team, including a Stanford M.D./Ph.D. and a Harvard Business School engineer.

What is the role of the SAIBRE platform in the partnership?

SAIBRE will analyze large volumes of data from Diagnose Early labs to aid in the early detection of diseases.

What is Sonasoft's stock symbol?

Sonasoft's stock symbol is SSFT.